<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00812682</url>
  </required_header>
  <id_info>
    <org_study_id>D5890L00021</org_study_id>
    <nct_id>NCT00812682</nct_id>
  </id_info>
  <brief_title>Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler</brief_title>
  <acronym>REALITY</acronym>
  <official_title>Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the perception of the physicians and the patients about the approved&#xD;
      adjustable dosing of SymbicortÂ® 160/4,5. Symbicort maintenance dose will be adjusted up and&#xD;
      down within the approved dose range of 1x2 - 4x2 inhalations per day, to the level of asthma&#xD;
      symptoms. Patients and physicians perception of this new dosing schedule will be evaluated by&#xD;
      means of questionnaires completion and direct questioning.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient satisfaction with the adjustable maintenance dosing schedule</measure>
    <time_frame>Throughout the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Physicians' satisfaction with the adjustable maintenance dosing schedule</measure>
    <time_frame>Throughout the study</time_frame>
  </primary_outcome>
  <enrollment type="Actual">217</enrollment>
  <condition>Perception of Physicians &amp; Patients of AMD</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary Care&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Minimum of 6 months history of asthma and treatment with an inhaled corticosteroids&#xD;
             for at least 3 months prior to visit 1 and/or a history of short term variation in&#xD;
             airway function and asthma symptoms responding promptly to convent&#xD;
&#xD;
          -  Patients where use of a combination (inhaled corticosteroid and long acting&#xD;
             beta2-agonist is appropriate, i.e. not controlled on inhaled corticosteroids alone).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Asthma exacerbation requiring oral corticosteroid treatment in the four weeks prior to&#xD;
             visit 1&#xD;
&#xD;
          -  Upper Respiratory Tract Infection in the previous four weeks&#xD;
&#xD;
          -  Severe cardiovascular disease or other significant concomitant disease, which may&#xD;
             interfere with the conduct of the study.&#xD;
&#xD;
          -  Women enrolled in the trial should not be planning pregnancy and should be taking&#xD;
             adequate contraceptive measures where appropriate.&#xD;
&#xD;
          -  Previous enrollment in a clinical study&#xD;
&#xD;
          -  Known or suspected hypersensitivity to budesonide, formoterol or inhaled lactose&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Panagiotis Pontikis, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical &amp; Regulatory Affairs Director, AstraZeneca Greece: 4</affiliation>
  </overall_official>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>December 19, 2008</study_first_submitted>
  <study_first_submitted_qc>December 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2008</study_first_posted>
  <last_update_submitted>January 21, 2011</last_update_submitted>
  <last_update_submitted_qc>January 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Panagiotis Pontikis, MD, Medical &amp; Regulatory Affairs Director, AstraZeneca Greece</name_title>
    <organization>AstraZeneca S.A., Greece</organization>
  </responsible_party>
  <keyword>SYMBICORT AMD</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

